Harvard Pilgrim Health Care | TUFTS Health Plan

Point32Health companies

Payment Policy:

Laboratory: Immunohistochemistry

Effective date: Nov. 1, 2025

Applies to:

Commercial Products

☒ Harvard Pilgrim Health Care Commercial products
☐ Tufts Health Plan Commercial products

Public Plans Products

☐ Tufts Health Direct – A Massachusetts Qualified Health Plan (QHP) (a commercial product)
☐ Tufts Health Together – MassHealth MCO Plan and Accountable Care Partnership Plans
☐ Tufts Health RITogether – A Rhode Island Medicaid Plan
☐ Tufts Health One Care – A dual-eligible product

Senior Products

☐ Tufts Health Plan Senior Care Options (SCO) (a dual-eligible product)
☐ Tufts Medicare Preferred HMO/PPO (Medicare Advantage products)

Policy

Immunohistochemistry (IHC) is a very sensitive and specific staining technique that uses anatomical, biochemical, and immunological methods to identify cells, tissues, and organisms by the interaction of target antigens with highly specific monoclonal antibodies and visualization though the use of a biochemical tag or label.

Indications and/or Limitations of Coverage

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request.

1. Code 88342 should be used for the first single antibody procedure and is reimbursed at one unit per specimen, up to four specimens, per date of service.
2. Code 88341 should be used for each additional single antibody per specimen and is reimbursed up to a maximum of 13 units per date of service.
3. Code 88344 should be used for each multiplex antibody per specimen, up to six specimens, per date of service

Applicable CPT/HCPCS Procedure Codes

Procedure codes appearing in policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

Coding

Code	Description
88341	Immunohistochemistry or immunocytochemistry, per specimen; each additional single antibody stain procedure
88342	Immunohistochemistry or immunocytochemistry, per spec; initial single antibody stain
88344	Immunohistochemistry or immunocytochemistry, per specimen; each multiplex antibody stain procedure

Evidence-based Scientific References

1. Fitzgibbons PL, Bradley LA, Fatheree LA, et al. Principles of analytic validation of immunohistochemical assays: Guideline from the College of American Pathologists Pathology and Laboratory Quality Center. Archives of pathology & laboratory medicine. Nov 2014;138(11):1432-43. doi:10.5858/arpa.2013-0610-CP
2. Tuffaha MSA, Guski H, Kristiansen G. Immunohistochemistry in Tumor Diagnostics. Immunohistochemistry in Tumor Diagnostics. 2018// 2018:1-9. doi:10.1007/978-3-319-53577-7_1

3. Lin F, Chen Z. Standardization of diagnostic immunohistochemistry: literature review and geisinger experience. Archives of pathology & laboratory medicine. Dec 2014;138(12):1564-77. doi:10.5858/arpa.2014-0074-RA
4. Kalra J, Baker J. Multiplex Immunohistochemistry for Mapping the Tumor Microenvironment. Methods Mol Biol. 2017;1554:237-251. doi:10.1007/978-1-4939-6759-9_17
5. Hofman P, Badoual C, Henderson F, et al. Multiplexed Immunohistochemistry for Molecular and Immune Profiling in Lung Cancer-Just About Ready for Prime-Time? Cancers (Basel). Feb 27 2019;11(3)doi:10.3390/cancers11030283
6. Shah AA, Frierson HF, Cathro HP. Analysis of Immunohistochemical Stain Usage in Different Pathology Practice Settings. 2012-12-01 2012;doi:10.1309/AJCPAGVTCKDXKK0X
7. Hainsworth J, Greco F. Overview of the classification and management of cancers of unknown primary site. Updated March 24, 2025. https://www.uptodate.com/contents/overview-of-the-classification-and-management-of-cancers-of-unknown-primary-site
8. Yamauchi H, Bleiweiss I. HER2 and predicting response to therapy in breast cancer. Updated July 31, 2025. https://www.uptodate.com/contents/her2-and-predicting-response-to-therapy-in-breast-cancer
9. Yamamoto H, Nozaki Y, Kohashi K, Kinoshita I, Oda Y. Diagnostic utility of pan-Trk immunohistochemistry for inflammatory myofibroblastic tumors. Histopathology. Oct 3 2019;doi:10.1111/his.14010
10. Lizotte PH, Ivanova EV, Awad MM, et al. Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes. JCI insight. Sep 8 2016;1(14):e89014. doi:10.1172/jci.insight.89014
11. Prok AL, Prayson RA. Thyroid transcription factor–1 staining is useful in identifying brain metastases of pulmonary origin. Annals of Diagnostic Pathology. 2006/04/01/ 2006;10(2):67-71. doi:10.1016/j.anndiagpath.2005.07.013
12. Le Stang N, Burke L, Blaizot G, et al. Differential Diagnosis of Epithelioid Malignant Mesothelioma With Lung and Breast Pleural Metastasis: A Systematic Review Compared With a Standardized Panel of Antibodies-A New Proposal That May Influence Pathologic Practice. Archives of pathology & laboratory medicine. Aug 7 2019;doi:10.5858/arpa.2018-0457-OA
13. Lin F, Liu H. Immunohistochemistry in undifferentiated neoplasm/tumor of uncertain origin. Archives of pathology & laboratory medicine. Dec 2014;138(12):1583-610. doi:10.5858/arpa.2014-0061-RA
14. Goldsmith JD, Troxell ML, Roy-Chowdhuri S, et al. Principles of Analytic Validation of Immunohistochemical Assays: Guideline Update. Archives of pathology & laboratory medicine. 2024;148(6):e111-e153. doi:10.5858/arpa.2023-0483-CP
15. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Nov 1 2013;31(31):3997-4013. doi:10.1200/jco.2013.50.9984
16. Wolff AC, Hammond MEH, Allison KH, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Jul 10 2018;36(20):2105-2122. doi:10.1200/jco.2018.77.8738
17. Wolff AC, Somerfield MR, Dowsett M, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO–College of American Pathologists Guideline Update. Journal of Clinical Oncology. 2023/08/01 2023;41(22):3867-3872. doi:10.1200/JCO.22.02864
18. NCCN. NCCN Guidelines Version 4.2025 Breast Cancer. Updated October 16, 2025. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
19. NCCN. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Colorectal Version 1.2025. Updated June 13, 2025. https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf
20. Krämer A, Bochtler T, Pauli C, et al. Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. Mar 2023;34(3):228-246. doi:10.1016/j.annonc.2022.11.013
21. Khoury JD, Wang WL, Prieto VG, et al. Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial. Clin Cancer Res. Feb 1 2018;24(3):521-531. doi:10.1158/1078-0432.Ccr-17-1597

Publication History

03/01/2026: Annual review; administrative edits
09/01/2025: Policy created to support coverage guidelines, effective for dates of service beginning Nov. 1, 2025

Background and Disclaimer Information

This policy applies to the products of Harvard Pilgrim Health Care and Tufts Health Plan and their affiliates, as identified in the check boxes on the first page for services performed by contracted providers.

Payment is based on member benefits and eligibility on the date of service, medical necessity review, where applicable, and the provider's network participation agreement with the Plan. As every claim is unique, this policy is neither a guarantee of payment, nor a final indication of how specific claim(s) will be adjudicated. Claims payment is subject to member eligibility and benefits on the date of service, coordination of benefits, referral/authorization, and utilization management requirements (when applicable),

adherence to Plan policies and procedures, and claims editing logic. An authorization is not a guarantee of payment.

Point32Health reserves the right to amend a payment policy at its discretion. CPT and HCPCS codes are updated as applicable; please adhere to the most recent CPT and HCPCS coding guidelines.

We reserve the right to conduct audits on any provider and/or facility to ensure accuracy and compliance with the guidelines stated in this payment policy. If such an audit determines that a provider/facility did not comply with this payment policy, Harvard Pilgrim Health Care and Tufts Health Plan will expect the provider/facility to refund all payments related to noncompliance.